Simvastatin Attenuates Oxidant-Induced Mitochondrial Dysfunction in Cardiac Myocytes

Circulation Research

Volumn 93, Issue 8, 2003, Pages 697-699

  Jones, Steven P ^b   Teshima, Yasushi ^b   Akao, Masaharu ^b   Marbán, Eduardo ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Mitochondria; Myocytes; Nitric oxide; Preconditioning; Statins

Indexed keywords

5 HYDROXYDECANOIC ACID; ESTER DERIVATIVE; HYDROGEN PEROXIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; POTASSIUM CHANNEL; RHODAMINE; SIMVASTATIN; TETRAMETHYLRHODAMINE ETHYL ESTER; UNCLASSIFIED DRUG; CARDIOTONIC AGENT; ENZYME INHIBITOR; MEMBRANE PROTEIN; MITOCHONDRIAL K(ATP) CHANNEL; NITRIC OXIDE SYNTHASE; OXIDIZING AGENT;

ANIMAL CELL; ARTICLE; CELL MEMBRANE DEPOLARIZATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; FLOW CYTOMETRY; FLUORESCENCE; HEART MITOCHONDRION; HEART MUSCLE CELL; HEART PROTECTION; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; NEWBORN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; ANIMAL; CELL CULTURE; CELL MEMBRANE POTENTIAL; DRUG ANTAGONISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CARDIOTONIC AGENTS; CELLS, CULTURED; ENZYME INHIBITORS; FLOW CYTOMETRY; HYDROGEN PEROXIDE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEMBRANE POTENTIALS; MEMBRANE PROTEINS; MITOCHONDRIA; MYOCYTES, CARDIAC; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; OXIDANTS; OXIDATIVE STRESS; POTASSIUM CHANNELS; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN;

EID: 0142120096     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000097262.21507.DF     Document Type: Article

References (21)

1. 4S Investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
2. Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res. 2001;49:281-287.
3. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 1998;95:8880-8885.
4. Jones SP, Lefer DJ. Cardioprotective actions of acute HMG-CoA reductase inhibition in the setting of myocardial infarction. Acta Physiol Scand. 2001;173:139-143.
5. Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem. 1997;272:31725-31729.
6. ATP channels in preconditioning. Circ Res. 2000;87:845-855.
7. Akao M, Ohler A, O'Rourke B, Marbán E. Mitochondrial ATP-sensitive potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells. Circ Res. 2001;88:1267-1275.
8. Jones SP, Trocha SD, Lefer DJ. Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion. Arterioscler Thromb Vasc Biol. 2001;21:2059-2064.
9. Akao M, O'Rourke B, Kusuoka H, Teshima Y, Jones SP, Marbán E. Differential actions of cardioprotective agents on the mitochondrial death pathway. Circ Res. 2003;92:195-202.
10. Akao M, O'Rourke B, Teshima Y, Seharaseyon J, Marbán E. Mechanistically distinct steps in the mitochondrial death pathway triggered by oxidative stress in cardiac myocytes. Circ Res. 2003;92:186-194.
11. Scalia R, Gooszen ME, Jones SP, Hoffmeyer M, Rimmer DM III, Trocha SD, Huang PL, Smith MB, Lefer AM, Lefer DJ. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation. 2001;103:2598-2603.
12. Lefer DJ, Scalia R, Jones SP, Sharp BR, Hoffmeyer MR, Farvid AR, Gibson MF, Lefer AM. HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury. FASEB J. 2001;15:1454-1456.
13. Jones SP, Gibson MF, Rimmer I, David M, Gibson TM, Sharp BR, Lefer DJ. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol. 2002;40:1172-1178.
14. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer D, Sessa W, Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1-7.
15. Sasaki N, Sato T, Ohler A, O'Rourke B, Marbán E. Activation of mitochondrial ATP-dependent potassium channels by nitric oxide. Circulation. 2000;101:439-445.
16. ATP channels in rat mitochondria. J Physiol. 2003;547(pt 3):893-902.
17. Oldenburg O, Cohen MV, Yellon DM, Downey JM. Mitochondrial KATP channels: role in cardioprotection. Cardiovasc Res. 2002;55:429-437.
18. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, Kitakaze M, Liao JK. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108:1429-1437.
19. Eto M, Kozai T, Cosentino F, Joch H, Luscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation. 2002;105:1756-1759.
20. Xie Y-W, Shen W, Zhao G, Xu X, Wolin MS, Hintze TH. Role of endothelium-derived nitric oxide in the modulation of canine myocardial mitochondrial respiration in vitro: implications for the development of heart failure. Circ Res. 1996;79:381-387.
21. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95:1126-1131.